These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32584790)

  • 1. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
    J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
    Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A
    J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent
    Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
    Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.
    Lee WS; Richard J; Lichtfuss M; Smith AB; Park J; Courter JR; Melillo BN; Sodroski JG; Kaufmann DE; Finzi A; Parsons MS; Kent SJ
    J Virol; 2016 Feb; 90(4):2021-30. PubMed ID: 26656700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells.
    Kong D; Wang Y; Ji P; Li W; Ying T; Huang J; Wang C; Wu Y; Wang Y; Chen W; Hao Y; Hong K; Shao Y; Dimitrov DS; Jiang S; Ma L
    AIDS; 2018 Aug; 32(13):1749-1761. PubMed ID: 29762173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies.
    Pham TN; Lukhele S; Dallaire F; Perron G; Cohen ÉA
    Sci Rep; 2016 Nov; 6():37225. PubMed ID: 27853288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.
    de Taeye SW; Schriek AI; Umotoy JC; Grobben M; Burger JA; Sanders RW; Vidarsson G; Wuhrer M; Falck D; Kootstra NA; van Gils MJ
    Commun Biol; 2024 Aug; 7(1):964. PubMed ID: 39122901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
    Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells.
    Richard J; Nguyen DN; Tolbert WD; Gasser R; Ding S; Vézina D; Yu Gong S; Prévost J; Gendron-Lepage G; Medjahed H; Gottumukkala S; Finzi A; Pazgier M
    mBio; 2021 Oct; 12(5):e0140521. PubMed ID: 34579568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG.
    Md Zahid H; Kuwata T; Takahama S; Kaku Y; Biswas S; Matsumoto K; Tamamura H; Matsushita S
    Retrovirology; 2021 Aug; 18(1):23. PubMed ID: 34419098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.